Asked by: Afzal Khan (Labour - Manchester Rusholme)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential implications for his policies of the report entitled The ADHD crisis in the UK – A Call to Action by ADHD360, published in January 2025.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
The Department is aware of the report, and officials will consider its findings, alongside wider evidence, in future policy development.
NHS England has established an attention deficit hyperactivity disorder (ADHD) taskforce which is working to bring together those with lived experience with experts from the National Health Service, education, charity and justice sectors to get a better understanding of the challenges affecting those with ADHD, including timely and equitable access to services and support, with the report expected in the summer.
For the first time, NHS England will publish management information on ADHD prevalence and waits at a national level on 29 May 2025 as part of its ADHD data improvement plan; it will soon release technical guidance to integrated care boards (ICBs) to improve recording of ADHD data, with a view to improving the quality of ADHD waits data. NHS England has also captured examples from ICBs who are trialling innovative ways of delivering ADHD services and is using this information to support systems to tackle ADHD waiting lists and provide support to address people’s needs.
Asked by: Afzal Khan (Labour - Manchester Rusholme)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he plans to take to reduce waiting times for ADHD diagnoses.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
It is the responsibility of the integrated care boards (ICBs) in England to make appropriate provision to meet the health and care needs of their local population, including attention deficit hyperactivity disorder (ADHD) assessments, in line with relevant National Institute for Health and Care Excellence guidelines.
NHS England has established an ADHD taskforce which is working to bring together those with lived experience with experts from the National Health Service, education, charity, and justice sectors to get a better understanding of the challenges affecting those with ADHD, including timely and equitable access to services and support, with the report expected in the summer.
For the first time, NHS England will publish management information on ADHD prevalence and waits at a national level on 29 May 2025, as part of its ADHD data improvement plan, and will soon release technical guidance to ICBs to improve the recording of ADHD data, with a view to improving the quality of ADHD waits data. NHS England has also captured examples from ICBs who are trialling innovative ways of delivering ADHD services, and is using this information to support systems to tackle ADHD waiting lists and to provide support to address people’s needs.
Asked by: Afzal Khan (Labour - Manchester Rusholme)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he has made an assessment of the potential merits of increasing funding for ADHD services.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
The ongoing Spending Review, which will be announced at my Rt. Hon. Friend, the Chancellor of the Exchequer’s Budget on 11 June, will set budgets for all areas of health.
Asked by: Afzal Khan (Labour - Manchester Rusholme)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he plans to introduce a national framework mandating GP acceptance of ADHD diagnoses from Right to Choose providers.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
There are no current plans to introduce a national framework mandating general practice (GP) acceptance of attention deficit hyperactivity disorder (ADHD) diagnoses from Right to Choose providers.
Shared care within the National Health Service refers to an arrangement whereby a specialist doctor formally transfers responsibility for all or some aspects of their patient’s care, such as the prescription of medication, over to the patient’s GP.
The General Medical Council (GMC) has issued guidance on prescribing and managing medicines, which helps GPs decide whether to accept shared care responsibilities. The GMC has made it clear that GPs cannot be compelled to enter into a shared care agreement. GPs may decline such requests on clinical or capacity grounds.
If a shared care arrangement cannot be put in place after the treatment has been initiated, the responsibility for continued prescribing falls upon the specialist clinician. This applies to both NHS and private medical care.
Asked by: Afzal Khan (Labour - Manchester Rusholme)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to promote the adoption of (a) digital technologies and (b) AI to support the transition of healthcare from treatment to prevention.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The National Health Service is already home to world-first digital innovation, with NHS England supporting the rollout of key products, many of which support the shift to prevention and early diagnosis. Examples include the world's first certified autonomous artificially intelligent (AI) diagnostic tool, which can triage patients with suspected skin cancer, as well as digital innovations supporting people struggling with mental health and musculoskeletal issues to gain or remain in employment.
NHS England, the National Institute for Health and Care Excellence, and the Department are developing a rules based pathway (RBP) for medical technology in the NHS. The RBP aims to create a clear, consistent, and efficient process for evaluating and adopting medical technologies, including digital technologies, in the NHS.
The Early Detection using Information Technology in Health, or EDITH trial, announced in February 2025, is backed by £11 million of Government support via the National Institute for Health and Care Research. It is the latest example of how British scientists are transforming cancer care, building on the promising potential of cutting-edge innovations to tackle one of the United Kingdom’s biggest killers.
Between October 2021 and May 2023 funding was invested in a risk-stratification tool to identify women who are at most risk of developing life-threatening and life-altering complications of pre-eclampsia.
Between October 2020 and September 2023, the Department invested £1.9 million in an AI stroke technology, capable of automatically processing acute stroke computed tomography or magnetic resonance imaging scans, which can provide real-time, clinically useful information in the acute stroke setting, leading to faster decisions.
Between October 2020 and September 2021 funding was invested towards generating a toolkit prototype which can automatically generate placental metrics from a 3D-US scan. These can be combined with other known risk factors and blood results to generate a multi-factorial screening test for fetal growth restriction, which is the single most common cause of stillbirth.
The deployment of AI in the NHS is still at a relatively early stage, with many AI tools being used in a research capacity. To address this, the Department is carrying out work, with NHS England, to assess the barriers of safe, ethical, and effective adoption, and improve the way AI tools are deployed and used in the NHS across England.
Asked by: Afzal Khan (Labour - Manchester Rusholme)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to increase levels of (a) diagnosis and (b) early disease detection through the adoption of AI.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Department has provided £113 million, through the NHS AI Health and Care Awards, to 86 artificial intelligence (AI) technologies, which have been live in 40% of National Health Service acute trusts in England and hundreds of primary care networks across the United Kingdom. This funding is helping us to generate the evidence needed to deploy effective AI tools across the NHS and improve the lives and health outcomes of our population.
Many of these AI technologies are being tested and evaluated to aid healthcare diagnostics. For example, AI is being used to analyse and interpret acute stroke brain scans, to support doctors making treatment decisions in 100% of stroke units in England. In addition, the Department is focusing the £21 million AI Diagnostic Fund on the deployment of technologies in key, high-demand areas such as chest X-ray and chest computed tomography scans, to enable faster diagnosis of lung cancer in over half of acute trusts in England.
Despite these exciting examples of AI use, deployment of AI in the NHS is still at a relatively early stage. To address this, the Department is carrying out work to assess the barriers of effective adoption and improve the way AI tools are deployed across the NHS.
Asked by: Afzal Khan (Labour - Manchester Rusholme)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure NHS Trusts meet digital capability targets.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
NHS England has supported over 160 trusts with digital transformation, which includes the implementation of Electronic Patient Records. Currently, we have achieved a 91% rollout of Electronic Patient Records, with work underway to provide tailored support to the remaining 19 trusts that do not yet have an Electronic Patient Record.
The Digital Maturity Assessment was also successfully completed in May 2024, with a 100% response rate from secondary care organisations and integrated care systems. This assessment provides a baseline and a holistic view of digital maturity across National Health Service trusts in England. The assessment will be run yearly to track progress and identify areas for improvement.
Asked by: Afzal Khan (Labour - Manchester Rusholme)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to help reduce gynaecology waiting lists in (a) Manchester Rusholme constituency and (b) Manchester.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Manchester University NHS Foundation Trust is the largest National Health Service trust serving both the Manchester Rusholme constituency and Manchester. At the end of January 2025, the waiting list for gynaecology services at the Manchester University Trust stood at 19,952, and in 42.7% of cases, the patient had been waiting up to 18 weeks. The median waiting time for gynaecology services at the Manchester University Trust was 21.8 weeks at the end of January 2025.
As set out in the Plan for Change, we have committed to return to the NHS constitutional standard that 92% of patients, including those waiting for gynaecological care, wait no longer than 18 weeks from referral to treatment by March 2029. We provided additional investment in the Autumn Budget that has enabled us to deliver an additional two million appointments as a first step to achieving this, seven months ahead of schedule.
The Elective Reform Plan, published in January 2025, sets out the reform we will undertake to return to the 18-week standard, and ensure patients have the best possible experience while they wait. This includes commitments to offer patients care closer to home, in the community, including piloting gynaecology pathways in community diagnostic centres for patients with unscheduled bleeding on hormone replacement therapy. We have also committed to increasing the relative funding available to support gynaecology procedures with the largest waiting lists and reviewing support options from the independent sector.
The Manchester University Foundation Trust is part of the Further Faster 20 initiative, which sees expert clinicians and managers deployed into NHS trusts in areas with the highest levels of economic inactivity to get patients treated faster. Greater Manchester is also served by four surgical hubs and seven community diagnostic centres.
Asked by: Afzal Khan (Labour - Manchester Rusholme)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department plans to allocate capital funding to improve stroke care infrastructure in Greater Manchester.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Government is committed to shifting the focus of the National Health Service out of hospitals and into the community through our 10-Year Health Plan, and we recognise that delivering high-quality NHS healthcare services requires the right infrastructure in the right places.
The Greater Manchester Integrated Care Board (ICB) has been provisionally allocated £5.6 million from our Primary Care Utilisation fund for 2025/26 to upgrade existing buildings and space, boosting productivity, and enabling practices to deliver more patient appointments.
In addition, the Greater Manchester ICB has been provisionally allocated £30.3 million from our Constitutional Standards Recovery fund to deliver new surgical hubs, diagnostic scanners, and beds to increase capacity for elective and emergency care.
In addition to national programme allocations, the Greater Manchester ICB has been provisionally allocated £194.5 million of operational capital funding, including primary care business as usual capital, which can be used to improve stroke care infrastructure, where this is a local priority.
Asked by: Afzal Khan (Labour - Manchester Rusholme)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent assessment his Department has made of the adequacy of the (a) availability and (b) eligibility requirements for NHS ADHD medication.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
NHS England has established an attention deficit hyperactivity disorder (ADHD) taskforce which is working to bring together those with lived experience with experts from the National Health Service, education, charity, and justice sectors. The taskforce is working to get a better understanding of the challenges affecting those with ADHD, including timely and equitable access to services and support, with the final report expected in the summer. In collaboration with NHS England’s national ADHD data improvement plan, we plan to combine modelling for future growth forecasts, which will be shared with industry to improve demand forecasting for ADHD medicines.
As a result of intensive work, some issues with ADHD medicines have resolved. However, whilst greatly improved, some supply issues persist for methylphenidate prolonged-release tablets and capsules. We are continuing to work to resolve these issues by engaging with all affected suppliers to assess the challenges faced and their actions to address them. We are also directing suppliers to secure additional stocks, expedite deliveries where possible, and review plans to build further capacity to support continued growth in demand for the short and long-term. The Department is also working with new suppliers of methylphenidate prolonged-release tablets to improve supply and resiliency for the United Kingdom’s market.
It is the responsibility of the integrated care boards in England to make available the appropriate provision to meet the health and care needs of their local population, including access to ADHD medication services, in line with relevant National Institute for Health and Care Excellence (NICE) guidelines.
It is for the responsible clinician to decide on the most appropriate treatment plan to manage ADHD, in discussion with their patient. This decision is based on the clinician’s expertise regarding treatment options, evidence, and risk and benefits, as well as the patient’s personal circumstances. The NICE’s guidelines on ADHD set out the considerations that healthcare professionals should take into account when considering treatment options.